8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 9, 2006

ev3 Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-51348		32-0138874
(State or Other Jurisdiction of Incorporation)	(Commission File Number)		(I.R.S. Employer Identification Number)
9600 54th Avenue North, Suite 100 Plymouth, Minnesota		55442
(Address of Principal Executive Offices)		(Zip Code)
(763) 398-7000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02.         Results of Operations and Financial Condition.

On January 9, 2006, ev3 Inc. issued a press release announcing its net sales results for its fiscal fourth quarter ended December 31, 2005.  A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filings made by ev3 Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as may be expressly set forth by specific reference in such filing.

Item 9.01          Financial Statements and Exhibits.

(c)  Exhibits.

Exhibit No.	Description
99.1	Press Release issuedJanuary 9, 2006

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 9, 2006	ev3 Inc.
	By:	/s/ Patrick D. Spangler
	Name:	Patrick D. Spangler
	Title:	Chief Financial Officer and Treasurer

3

EXHIBIT INDEX

Exhibit No.	Description	Method of Filing
99.1	Press Release issued January 9, 2006	Furnished herewith

4

EX-99.1

Exhibit 99.1

CONTACT:

Patrick D. Spangler, CFO

ev3 Inc.

9600 54^th Avenue North

Plymouth, Minnesota  55442-2920

(763) 398-7000

pspangler@ev3.net

ev3 Inc. Reports Fourth Quarter Net Sales

Net Sales Grow by 60% Compared to Year-Ago Period

Plymouth, MN – January 9, 2006 – ev3 Inc. (NASDAQ:  EVVV), a global endovascular device company, reported today net sales results for its fiscal fourth quarter ended December 31, 2005.

ev3’s net sales in the fourth quarter of 2005 were $41.0 million, an increase of 60% versus net sales of $25.5 million in the fourth quarter of 2004. This growth was broad-based and generated internally, reflecting strong sales growth from domestic and international markets as well as from both ev3’s cardio peripheral and neurovascular business segments.

Cardio peripheral segment net sales in the fourth quarter were $24.0 million, representing an increase of 58% versus the year-ago quarter.  Within the cardio peripheral business segment, stent sales were $12.1 million in the fourth quarter, representing an increase of 112% versus the year-ago quarter, and sales of thrombectomy and embolic protection products were $3.5 million in the fourth quarter, approximately unchanged from the year-ago quarter.  Sales of procedural support and other cardio peripheral products were $8.4 million in the fourth quarter, representing an increase of 40% versus the year-ago quarter.  Contributors to the growth of the cardio peripheral segment were the launch of new stent products in the United States, the continued market penetration of ev3’s carotid stenting system (SpideRX and Protégé) in Europe, and the introduction of PTA balloon catheters in early 2005.

Neurovascular segment net sales were $17.0 million in the fourth quarter, representing an increase of 64% versus the year-ago quarter.   Within the neurovascular business segment, sales of embolic products were $8.0 million in the fourth quarter, an increase of 89% versus the same quarter in the prior year.  Sales of neurovascular access and delivery products were $9.0 million in the fourth quarter, an increase of 46% versus the year-ago quarter.  The primary growth drivers for the neurovascular segment were the continued U.S. market penetration by both the Onyx Liquid Embolic System for the treatment of brain arterio-venous malformations (“AVMs”) and the NXT family of embolic coils, as well as the microcatheters utilized to deliver these embolic products.

On a geographic basis, ev3’s fourth quarter United States net sales were $22.7 million, representing an increase of 91% versus the year-ago quarter, and fourth quarter international net sales were $18.3 million, representing an increase of 34% versus the year-ago quarter.   Sales growth in the United States benefited from the increased productivity of the sales force which was expanded during the fourth quarter of 2004 in both the cardio peripheral and neurovascular business segments.

For the fiscal year ended December 31, 2005, ev3’s net sales were $133.7 million, an increase of 55% compared to net sales for fiscal 2004.  Annual sales growth in 2005 also was generated internally and reflected net sales growth in each of ev3’s reportable business segments and geographic markets.

Clinical Trial and Regulatory Update

On January 6, 2006, ev3 submitted a pre-market approval application to the FDA for a carotid stenting system which combines ev3’s SpideRX embolic protection device and ev3’s Protégé stent, and which was clinically studied in ev3’s 419 patient CREATE I Carotid stenting pivotal trial. ev3 anticipates FDA approval for this indication by the end of 2006.  ev3 previously submitted 510(k) applications for its

SpideRX for saphenous vein graft angioplasty and for carotid stenting with the Guidant Acculink stent.  ev3 anticipates mid-year 2006 FDA clearance of these 510(k)s.

 ev3 will be providing full financial results for its fiscal fourth quarter and fiscal year 2005 and updated guidance in mid-February, after which time the Company will hold its quarterly conference call to discuss its financial results and guidance.

ev3 Inc. is a global medical device company focused on endovascular technologies for the minimally invasive treatment of vascular diseases and disorders.

Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied.  Such potential risks and uncertainties relate, but are not limited, to, in no particular order:  product demand and market acceptance, the impact of competitive products and pricing, and success of clinical testing.  More detailed information on these and additional factors which could affect ev3 Inc.’s operating and financial results are described in the company’s filings with the Securities and Exchange Commission, including its most recent quarterly report on Form 10-Q.  ev3 Inc. urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces.  Additionally, ev3 Inc. undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.

ev3 Inc.

SELECTED NET SALES INFORMATION

(Dollars in thousands)

(unaudited)

	For the Three Months Ended December 31,				For the Years Ended December 31,
NET SALES BY SEGMENT	2005		2004		2005		2004
Cardio Peripheral
Stents	$	12,079	$	5,707	$	37,871	$	20,484
Thrombectomy and embolic protection	3,459		3,436		12,869		9,119
Procedural support and other	8,451		6,019		29,141		23,339
Total Cardio Peripheral	23,989		15,162		79,881		52,942
Neurovascular
Embolic products	8,046		4,246		22,463		12,583
Neuro access and delivery products	8,939		6,123		31,352		20,809
Total Neurovascular	16,985		10,369		53,815		33,392
Total Company	$	40,974	$	25,531	$	133,696	$	86,334

	For the Three Months Ended December 31,				For the Years Ended December 31,
NET SALES BY GEOGRAPHY	2005		2004		2005		2004
United States	$	22,707	$	11,903	$	71,848	$	42,791
International	18,267		13,628		61,848		43,543
Total Company	$	40,974	$	25,531	$	133,696	$	86,334